Mano Horinaka

Profile Information

Affiliation: Associate Professor, Graduate School of Medical Science, Kyoto Prefectural University of Medicine

J-GLOBAL ID: 201801001341648879
researchmap Member ID: B000316085

Research Areas

Papers

Coffee extracts and caffeine upregulate the expression of the immune checkpoint factors, PD‑1 and PD‑L1

Tatsushi Yoshida, Kenta Yamasaki, Mano Horinaka, Kenjiro Tadagaki

International Journal of Functional Nutrition, 5(1), Apr 19, 2024
Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells.

Soichi Hirai, Tadaaki Yamada, Yuki Katayama, Masaki Ishida, Hayato Kawachi, Yohei Matsui, Ryota Nakamura, Kenji Morimoto, Mano Horinaka, Toshiyuki Sakai …

Molecular cancer therapeutics, 23(2) 212-222, Feb 1, 2024
KRAS-G12C陽性肺がんにおけるAXLの活性化を介したKRAS-G12C阻害薬初期治療抵抗性(Adaptive resistance to KRAS-G12C inhibitors through AXL activation in KRAS-G12C mutant tumor cells)

森本健司, 山田忠明, 平井聡一, 片山勇輝, 矢野聖二, 堀中真野, 酒井敏行, 徳田深作, 高山浩一

日本癌学会総会記事, 82回 111-111, Sep, 2023
RET変異がんにおけるHER3活性化を介したセルペルカチニブに対する治療抵抗性に関する基礎的検討(Intrinsic resistance to selpercatinib via HER3 signaling in RET aberrant cancercells)

片山勇輝, 山田忠明, 谷村恵子, 森本健司, 矢野聖二, 堀中真野, 酒井敏行, 高山浩一

日本癌学会総会記事, 82回 115-115, Sep, 2023
Cancer-Cell-Selective Targeting by Arylcyclopropylamine–Vorinostat Conjugates

Yosuke Ota, Yukihiro Itoh, Takashi Kurohara, Ritesh Singh, Elghareeb E. Elboray, Chenliang Hu, Farzad Zamani, Anirban Mukherjee, Yuri Takada, Yasunobu Yamashita …

ACS Medicinal Chemistry Letters, 13(10) 1568-1573, Oct 13, 2022 Peer-reviewed
ALK融合遺伝子陽性肺がんにおけるEGFRシグナル活性化を介したロルラチニブ初期治療抵抗性の解明とその克服(Adaptive resistance to lorlatinib by EGFR activation in ALK-rearranged non-small cell lung cancer cells)

片山勇輝, 谷村恵子, 森本健司, 堀中真野, 酒井敏行, 小笹裕晃, 山田忠明

日本癌学会総会記事, 81回 J-2014, Sep, 2022
Citrus limon L.-Derived Nanovesicles Show an Inhibitory Effect on Cell Growth in p53-Inactivated Colorectal Cancer Cells via the Macropinocytosis Pathway

Hideki Takakura, Toshimasa Nakao, Takumi Narita, Mano Horinaka, Yukako Nakao-Ise, Tetsushi Yamamoto, Yosuke Iizumi, Motoki Watanabe, Yoshihiro Sowa, Keisuke Oda …

Biomedicines, 10(6) 1352-1352, Jun 8, 2022 Peer-reviewed
Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR-T790M mutation in non-small cell lung cancer cells.

Yuki Katayama, Tadaaki Yamada, Shinsaku Tokuda, Naoko Okura, Naoya Nishioka, Kenji Morimoto, Keiko Tanimura, Yoshie Morimoto, Masahiro Iwasaku, Mano Horinaka …

Cancer medicine, 11(4) 944-955, Feb, 2022 Peer-reviewed
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features.

Keiko Tanimura, Tadaaki Yamada, Koutaroh Okada, Kunihiro Nakai, Mano Horinaka, Yuki Katayama, Kenji Morimoto, Yuri Ogura, Takayuki Takeda, Shinsuke Shiotsu …

NPJ precision oncology, 6(1) 5-5, Jan 18, 2022
Sodium salicylate and 5-aminosalicylic acid synergistically inhibit the growth of human colon cancer cells and mouse intestinal polyp-derived cells

Hideki Takakura, Mano Horinaka, Ayaka Imai, Yuichi Aono, Toshimasa Nakao, Shingo Miyamoto, Yosuke Iizumi, Motoki Watanabe, Takumi Narita, Hideki Ishikawa …

Journal of Clinical Biochemistry and Nutrition, 70(2) 93-102, 2022 Peer-reviewed
Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer.

Keiko Tanimura, Tadaaki Yamada, Mano Horinaka, Yuki Katayama, Sarina Fukui, Kenji Morimoto, Takayuki Nakano, Shinsaku Tokuda, Yoshie Morimoto, Masahiro Iwasaku …

Cancer letters, 522 119-128, Dec 1, 2021
新規がん予防標的GGCTは、がん細胞にHIF-1 alpha発現を誘導して好気性解糖を促進する

谷口恵香, 影山進, 茂山千愛美, 安藤翔太, 飯居宏美, 芦原英司, 堀中真野, 酒井敏行, 河内明宏, 中田晋

日本衛生学雑誌, 76(Suppl.) S158-S158, Mar, 2021
The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway

Ono, H., Sowa, Y., Horinaka, M., Iizumi, Y., Watanabe, M., Morita, M., Nishimoto, E., Taguchi, T., Sakai, T.

Breast Cancer Research and Treatment, 171(1) 43-52, 2018 Peer-reviewed
sulindac sulfideは転写因子MZF1を介してDR5の発現を誘導し、癌細胞のTRAIL感受性を増強する

堀中真野, 吉田達士, 曽和義広, 酒井敏行

日本癌学会総会記事, 74回 P-1188, Oct, 2015
Myeloid zinc finger 1 mediates sulindac sulfide-induced upregulation of death receptor 5 of human colon cancer cells

Mano Horinaka, Tatsushi Yoshida, Mitsuhiro Tomosugi, Shusuke Yasuda, Yoshihiro Sowa, Toshiyuki Sakai

SCIENTIFIC REPORTS, 4(6000), Aug, 2014 Peer-reviewed
Targeting the Glyoxalase Pathway Enhances TRAIL Efficacy in Cancer Cells by Downregulating the Expression of Antiapoptotic Molecules

Hiroya Taniguchi, Mano Horinaka, Tatsushi Yoshida, Kimihiro Yano, Ahmed E. Goda, Shusuke Yasuda, Miki Wakada, Toshiyuki Sakai

MOLECULAR CANCER THERAPEUTICS, 11(10) 2294-2300, Oct, 2012 Peer-reviewed
Aclarubicin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis through death receptor 5 upregulation

Mano Horinaka, Tatsushi Yoshida, Susumu Nakata, Takumi Shiraishi, Mitsuhiro Tomosugi, Sae Yoshikawa, Miki Wakada, Toshiyuki Sakai

CANCER SCIENCE, 103(2) 282-287, Feb, 2012 Peer-reviewed
Chetomin induces degradation of XIAP and enhances TRAIL sensitivity in urogenital cancer cells

Kimihiro Yano, Mano Horinaka, Tatsushi Yoshida, Takashi Yasuda, Hiroya Taniguchi, Ahmed E. Goda, Miki Wakada, Sae Yoshikawa, Terukazu Nakamura, Akihiro Kawauchi …

INTERNATIONAL JOURNAL OF ONCOLOGY, 38(2) 365-374, Feb, 2011 Peer-reviewed
"Combination-oriented Molecular-Targeting Prevention" of cancer: A model involving the combination of TRAIL and a DR5 inducer

Tatsushi Yoshida, Mano Horinaka, Toshiyuki Sakai

Environmental Health and Preventive Medicine, 15(4) 203-210, Jul, 2010 Peer-reviewed
Cyclin-dependent kinase inhibitor SU9516 enhances sensitivity to methotrexate in human T-cell leukemia Jurkat cells

Hitoji Uchiyama, Yoshihiro Sowa, Miki Wakada, Mayumi Yogosawa, Ryoko Nakanishi, Mano Horinaka, Chihiro Shimazaki, Masafumi Taniwaki, Toshiyuki Sakai

CANCER SCIENCE, 101(3) 728-734, Mar, 2010 Peer-reviewed

Misc.

スリンダク代謝体であるスリンダクスルホンによる大腸癌細胞増殖抑制作用の機序の解明に向けた新規標的分子の同定(Sulindac sulfone inhibits the mTORC1 pathway in colon cancer cells by directly targeting VDAC1 and VDAC2)

青野裕一, 堀中真野, 飯泉陽介, 安田周祐, 渡邉元樹, 酒井敏行

日本癌学会総会記事, 78回 J-3026, Sep, 2019
The novel combination treatment of a HDAC inhibitor OBP-801 with eribulin for triple-negative breast cancer cells

Hisako Ono, Yoshihiro Sowa, Mano Horinaka, Yosuke Iizumi, Motoki Watanabe, Tetsuya Taguchi, Toshiyuki Sakai

CANCER SCIENCE, 109 559-559, Dec, 2018
トリプルネガティブ乳癌細胞に対する新たな併用療法HDAC阻害剤OBP-801とエリブリン(The novel combination treatment of a HDAC inhibitor OBP-801 with eribulin for triple-negative breast cancer cells)

小野寿子, 曽和義広, 堀中真野, 飯泉陽介, 渡邉元樹, 田口哲也, 酒井敏行

日本癌学会総会記事, 77回 594-594, Sep, 2018
グリオキサラーゼ経路に対する標的治療は抗アポトーシス因子の発現抑制を介し癌細胞でのTRAILによるアポトーシス誘導を増強する(Targeting glyoxalase pathway enhances TRAIL efficacy by down-regulating the expression of anti-apoptotic molecules)

谷口浩也, 堀中真野, 矢野公大, 酒井敏行

日本癌学会総会記事, 72回 292-292, Oct, 2013
アクラルビシンによるDR5発現誘導を介したTRAIL感受性増強効果(Aclarubicin enhances TRAIL-induced apoptosis through DR5 up-regulation)

堀中真野, 吉田達士, 中田晋, 白石匠, 友杉充宏, 三木恒治, 酒井敏行

日本癌学会総会記事, 71回 120-120, Aug, 2012
酪酸菌による好中球からのTRAIL誘導とその抗腫瘍効果の検討(The stimulation of Clostridium butyricum on neutrophils causes the release of TRAIL)

神農雅秀, 堀中真野, 本郷文弥, 高羽夏樹, 河内明宏, 三木恒治, 酒井敏行

日本癌学会総会記事, 70回 373-373, Sep, 2011
Lactobacillus plantarum induces TRAIL production and facilitates natural killer activity against cancer cells

Mano Horinaka, Tatsushi Yoshida, Atsuko Kishi, Kaoru Akatani, Takashi Yasuda, Junji Kouhara, Miki Wakada, Toshiyuki Sakai

CANCER RESEARCH, 71, Apr, 2011
植物リグナンNDGAによるDR5遺伝子の発現誘導とTRAIL誘導性アポトーシスの増強

安田考志, 吉田達士, 白石匠, 堀中真野, 中田晋, Ahmed Goda, 水谷陽一, 三木恒治, 西川秋佳, 酒井敏行

日本衛生学雑誌, 64(2) 630-630, Mar, 2009
NDGAによるDR5遺伝子の発現誘導とTRAIL誘導性アポトーシスの増強(Lipoxygenase inhibitors induce DR5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis)

堀中真野, 吉田達士, 白石匠, 中田晋, 安田考志, Goda Ahmed, 水谷陽一, 三木恒治, 西川秋佳, 酒井敏行

日本癌学会総会記事, 67回 383-383, Sep, 2008
Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize the DU145 human prostate cancer cell line to trail-induced apoptosis

Takumi Shiraishi, Tatsushi Yoshida, Takashi Yasuda, Terukazu Nakamura, Kazuya Mikami, Natsuki Takaha, Mano Horinaka, Susumu Nakata, Ahmed E. Goda, Akiyoshi Nishikawa …

JOURNAL OF UROLOGY, 179(4) 388-389, Apr, 2008
baicaleinはDR5発現を上昇させ癌細胞特異的にTRAIL誘導性アポトーシスを増強する

谷口浩也, 吉田達志, 堀中真野, 若田未来, 酒井敏行

日本衛生学雑誌, 63(2) 408-408, Mar, 2008
食餌性フラボノイドのアピゲニンは悪性腫瘍細胞の腫瘍壊死因子関連アポトーシス誘導性リガンドに対する感受性を増強する(Dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand)

堀中真野, 吉田達士, 白石匠, 中田晋, 酒井敏行

日本癌学会総会記事, 66回 365-365, Aug, 2007
結腸癌細胞株においてfenretinideはDR5を上方制御し、TRAILと相乗的にアポトーシスを誘導する(Fenretinide up-regulates DR5 and induces synergistic apoptosis with TRAIL in colon cancer cell lines)

甲原純二, 吉田達士, 中田晋, 堀中真野, 上田祐二, 大辻英吾, 山岸久一, 酒井敏行

日本癌学会総会記事, 66回 365-365, Aug, 2007
Proteasome inhibitor MG132 induces death receptor 5 (DR5) through CCAAT/enhancer-binding protein homologous protein (CHOP) and enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/AP02L)-induced apoptosis in DU145, human hormone-independent prostate cancer cells

T Shiraishi, T Yoshida, Y Mizutani, T Yasuda, T Nakamura, T Nomoto, A Kawauchi, S Nakata, M Horinaka, T Sakai …

JOURNAL OF UROLOGY, 175(4) 140-140, Apr, 2006
癌の「分子標的併用予防法」の開発 FenretinideによるDR5遺伝子の発現誘導とTRAIL誘導性アポトーシスの増強

甲原純二, 吉田達士, 中田晋, 堀中真野, 若田未来, 山岸久一, 酒井敏行

日本衛生学雑誌, 61(2) 247-247, Mar, 2006
ルテオリンは癌細胞のDR5の発現を活性化しアポトーシスを誘導する

堀中真野, 吉田達士, 白石匠, 中田晋, 西野輔翼, 酒井敏行

日本癌学会総会記事, 64回 518-518, Sep, 2005

Research Projects

ヘビの防御物質ブファジエノライド：食性進化のメカニズム解明

科学研究費助成事業, 基盤研究(A), 日本学術振興会, Apr, 2021 - Mar, 2026

森直樹, 森哲, 中崎敦夫, 木村泰久, 酒井敏行, 堀中真野, 栗山長門
Tailor-maid cancer prevention towards the era of preemptive medicine.

Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (A), Japan Society for the Promotion of Science, Apr, 2019 - Mar, 2024
Preventive strategy against arsenic carcinogenesis by TRAIL pathway activation and RB activation

Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (B), Japan Society for the Promotion of Science, Apr, 2019 - Mar, 2023
Research of molecular-targeting prevention against inflammatory diseases using chemical biology.

Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research on Innovative Areas (Research in a proposed research area), Japan Society for the Promotion of Science, Jun, 2017 - Mar, 2022

Sakai Toshiyuki
Combination-oriented molecular-targeting prevention of cancer : targeting TRAIL and microRNA.

Grants-in-Aid for Scientific Research, Grant-in-Aid for Young Scientists (Start-up), Japan Society for the Promotion of Science, 2008 - 2009

HORINAKA Mano
TRAILとDR5を標的とした癌の「分子標的併用療法」の開発

科学研究費助成事業, 特定領域研究, 日本学術振興会, 2008 - 2009

酒井敏行, 曽和義広, 与五沢真吾, 堀中真野
Research on a selection reference of chemopreventive agents for cancer and a development of tailor-made medicine for cancer prevention

Grants-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (A), Japan Society for the Promotion of Science, 2005 - 2008

SAKAI Toshiyuki, SOWA Yoshihiro, MATSUZAKI Yoichiro, YOSHIDA Tatsushi, YOGOSAWA Shingo, HORINAKA Mano

Profile Information

Research Areas

Papers

Misc.

Research Projects

Menu

Coauthors